Pfizer (PFE) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
PFIZER REPORTS THIRD-QUARTER 2018 RESULTS
October 30, 2018 6:45 AM EDTThird-Quarter 2018 Revenues of $13.3 Billion, Reflecting 2% Operational Growth Third-Quarter 2018 Reported Diluted EPS(1) of $0.69, Adjusted Diluted EPS(2) of $0.78 Narrowed Certain 2018 Financial Guidance Ranges; Midpoint of Updated Adjusted Diluted EPS(2) Guidance Range of $2.98 to $3.02 is Unchanged from July 2018 Repurchased $1.1 Billion of Common Stock in Third-Quarter 2018 and $9.0 Billion to Date in 2018; Now Expect to Repurchase Approximately $12 Billion of Shares in 2018
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2018 and narrowed certain 2018 financial guidance ranges.
Results for the third quarter and first nine months of 2018 and 2017(3) are summarized below.
OVERALL RESULTS... More